Translocations of the MLL (Mixed Lineage Leukemia) gene are frequently found in human leukemias affecting both children and adults. Fusion of MLL to one of more than 60 genes results in generation of oncogenic proteins upregulating Hox genes, which are vital to blood cell development. Patients harboring fusion of the MLL gene suffer from aggressive leukemias and respond poorly to available therapies. All of the oncogenic fusion proteins have a preserved N-terminal fragment of MLL that has been identified to interact with menin. It has been recently discovered that association with menin is critical to the leukemogenic activity of the MLL fusion oncoproteins. Selective targeting of the menin-MLL interaction could provide an attractive therapeutic approach to develop novel drugs for MLL-related leukemias. Small molecules blocking the menin-MLL interaction should reverse the oncogenic potential of MLL fusion proteins. We have developed and optimized a fluorescence polarization-based assay for the identification of Menin-MLL inhibitors. The assay was run employing two different MLL-derived peptides. The present assay uses a 12 amino acid peptide labeled with fluorescein at its N-terminus. This peptide consists of the menin high affinity binding motif from MLL and is potently bound by menin. Another peptide with a mutated sequence, labeled with Texas Red, was used in parallel as a less stringent screen for inhibitors. The present assay was developed to confirm hits from this primary screen, examining saturation transfer differences in NMR spectra upon incubation of the menin protein with compound. The Menin protein, the MLL-wild type (w.t.) derived peptide (N-terminal 12 amino acids), the MLL-derived peptide labeled with Texas Red and the MLL-w.t. peptide labeled with Fluorescein were kindly supplied by laboratory of Dr. Jolanta Grembecka, University of Virginia. All protein and peptide solutions were stored in single use aliquots at -80C. The Buffer components for all assays were purchased from Sigma-Aldrich (St. Louis, MO) and Invitrogen (Carlsbad, CA). Assay Reagents: 1. Menin protein 2. MLL w.t. 3. NMR buffer: 50mM phosphate, 50mM NaCl, 1mM DTT, pH = 7.5 NMR protocol: 1. Prepare 450 uL of menin (2.5 uM) in complex with 100uM compound in NMR buffer and run STD (Saturation Transfer Difference) on NMR Bruker 600 MHz 2. Prepare 450 uL of menin (2.5 uM) in complex with 100 uM compound and 25uM of MLL w.t. in NMR buffer and run STD (Saturation Transfer Difference) on NMR Bruker 600 MHz
bao:BAO_0001077 "1766" ; # "is alternate confirmatory assay of" -> "1766"
bao:BAO_0001077 "1768" ; # "is alternate confirmatory assay of" -> "1768"
bao:BAO_0000812 "2076" ; # "has summary assay" -> "2076"
bao:BAO_0000210 bao:BAO_0000032 ; # "has assay stage" -> "secondary assay"
bao:BAO_0001078 bao:BAO_0001096 ; # "has orthogonal assay technology" -> "orthogonal assay technology"
bao:BAO_0000205 bao:BAO_0000217 ; # "has assay format" -> "biochemical format"
bao:BAO_0000205 bao:BAO_0000224 ; # "has assay format" -> "protein format"
bao:BAO_0000205 bao:BAO_0000223 ; # "has assay format" -> "protein complex format"
bao:BAO_0000409 bao:BAO_0000410 ; # "assay measurement type" -> "endpoint assay"
bao:BAO_0002850 bao:BAO_0000534 ; # "has assay readout content" -> "single readout"
bao:BAO_0002851 "single parameter" ; # "has assay readout content parametricity" -> "single parameter"
bao:BAO_0000399 bao:BAO_0000282 ; # "has transcription factor" -> "transcription factor"
bao:BA0_0090012 bao:BAO_0000292 ; # "has participant" -> "transferase" || bao:BAO_0003102 bao:BAO_00020144 ; # "has role" -> "target"
bao:BAO_0002855 bao:BAO_00020101 ; # "is bioassay type of" -> "protein-protein interaction assay"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "Menin/MLL" ; # "protein-protein" -> "Menin/MLL"
bao:BAO_0000212 bao:BAO_0000123 ; # "has assay method" -> "binding assessment method"
bao:BAO_0000207 bao:BAO_0000160 ; # "has detection method" -> "nuclear magnetic resonance"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "Identification for inhibitors targeting the Menin-MLL interaction in MLL related leukemias" ; # "screening campaign name" -> "Identification for inhibitors targeting the Menin-MLL interaction in MLL related leukemias"
bao:BAO_0002853 "Confirmation of Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: NMR spectroscopy to verify direct binding of compounds to menin." ; # "has assay title" -> "Confirmation of Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: NMR spectroscopy to verify direct binding of compounds to menin."
bao:BAO_0003105 <http://purl.obolibrary.org/obo/GO_0005488> ; # "has function" -> "binding"
bao:BAO_0002863 bao:BAO_0000536 ; # "has concentration throughput" -> "single concentration"
bao:BAO_0000109 "25 degree celsius" ; # "has temperature value" -> "25 degree celsius"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "Jolanta Grembecka" ; # "material entity assay provider" -> "Jolanta Grembecka"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "Tomasz Cierpicki" ; # "material entity assay provider" -> "Tomasz Cierpicki" || bao:BAO_0003102 bao:BAO_0000027 ; # "has role" -> "assay provider"
bao:BAO_0002020 bao:BAO_0000372 ; # "has assay phase characteristic" -> "homogeneous phase"
bao:BA0_0090012 bao:BAO_0000895 ; # "has participant" -> "DTT" || bao:BAO_0003102 <http://purl.obolibrary.org/obo/CHEBI_63247> ; # "has role" -> "reducing agent"
bao:BA0_0090012 "Menin" ; # "has participant" -> "Menin"
bao:BA0_0090012 "Histone-lysine N-methyletransferase MLL" ; # "has participant" -> "Histone-lysine N-methyletransferase MLL"
bao:BAO_0002921 <http://purl.obolibrary.org/obo/NCBITaxon_9606> ; # "has organism" -> "Homo sapiens"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "Q03164" ; # "uniprot ID" -> "Q03164"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "O00255" ; # "uniprot ID" -> "O00255"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "9606" ; # "NCBI taxonomy ID" -> "9606"
bao:BAO_0002662 bao:BAO_0002157 ; # "has quality" -> "native form"
bao:BAO_0002897 bao:BAO_0000360 ; # "has preparation method" -> "recombinant expression"
bao:BAO_0002857 bao:BAO_0002153 ; # "has signal direction" -> "signal increase corresponding to inhibition"
bao:BA0_0090012 bao:BAO_0000176 ; # "has participant" -> "small molecule" || bao:BAO_0003102 bao:BAO_00020137 ; # "has role" -> "perturbagen"
bao:BAO_0000212 bao:BAO_0000574 ; # "has assay method" -> "single perturbagen"
bao:BAO_0002865 bao:BAO_0002719 ; # "uses detection instrument" -> "Avance III"
bao:BAO_0000737 bao:BAO_0002654 ; # "has manufacturer" -> "Bruker" || bao:BAO_0003102 bao:BAO_0002628 ; # "has role" -> "instrumentation manufacturer"
bao:BAO_0000208 bao:BAO_0000583 ; # "has endpoint" -> "raw activity"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "1" ; # "PubChem TID" -> "1"
bao:BAO_0002666 "100" ; # "has concentration value" -> "100"
bao:BAO_0000183 <http://purl.org/obo/owl/UO#UO_0000064> ; # "has concentration unit" -> "micromolar"
bao:BAO_0002787 "1" ; # "has concentration-point number" -> "1"
bao:BAO_0002845 "1" ; # "has repetition point-number" -> "1"
bao:BAO_0000196 bao:BAO_0000579 ; # "has mode of action" -> "saturation binding"
bao:BAO_0002864 bao:BAO_0000136 ; # "has repetition throughput" -> "single repetition"
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> "ahsan" ; # "Annotated by" -> "ahsan"
